Nkarta, Inc.

Nkarta, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to advancing and marketing cell-based treatments for cancer. Their innovative cellular immunotherapy strategy outfits natural killer (NK) cells with chimeric antigen receptors (CARs) on their surface, allowing these cells to pinpoint particular proteins or antigens found on the exterior of tumor cells. The company's primary investigational products include NKX101, which is undergoing Phase I human trials for resistant or recurring acute myeloid leukemia and high-risk myelodysplastic syndromes. Another key candidate is NKX019, a pre-clinical asset designed to combat various B-cell malignancies by targeting the CD19 antigen present on these cancerous cells. Furthermore, Nkarta maintains a collaborative research partnership with CRISPR Therapeutics AG. Founded in 2015, the company's main operations are situated in South San Francisco, California.